{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:37:19Z","timestamp":1757608639633,"version":"3.44.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,2]]},"DOI":"10.7759\/cureus.91510","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:42:24Z","timestamp":1756878144000},"source":"Crossref","is-referenced-by-count":0,"title":["Challenges and Opportunities of Early Parkinson\u2019s Disease Biomarkers: \u03b1-Synuclein, Leucine-Rich Repeat Kinase 2 (LRRK2), DJ-1, and microRNAs"],"prefix":"10.7759","author":[{"given":"Allie","family":"Heineman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian","family":"Linck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Eylon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur S","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009282","article-title":"Motor control abnormalities in Parkinson's disease","volume":"2","author":"Mazzoni P","year":"2012","unstructured":"Mazzoni P, Shabbott B, Cort\u00e9s JC. Motor control abnormalities in Parkinson's disease. Cold Spring Harb Perspect Med. 2012, 2:a009282. 10.1101\/cshperspect.a009282","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184262","article-title":"The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome","volume":"12","author":"Park HJ","year":"2017","unstructured":"Park HJ, Ryu D, Parmar M, Giasson BI, McFarland NR. The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. PLoS One. 2017, 12:e0184262. 10.1371\/journal.pone.0184262","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2017.02.027","article-title":"PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson's disease","volume":"645","author":"Miki Y","year":"2017","unstructured":"Miki Y, Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K. PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson's disease. Neurosci Lett. 2017, 645:40-5. 10.1016\/j.neulet.2017.02.027","journal-title":"Neurosci Lett"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.90.15_supplement.P3.049","article-title":"Rab8a protects against alpha-synuclein toxicity in a rat model of Parkinsonism (P3.049)","volume":"90","author":"McFarland N","year":"2018","unstructured":"McFarland N, Parmar M, Park HJ, Ryu D, Powell L, Foels R, Anagnostis S. Rab8a protects against alpha-synuclein toxicity in a rat model of Parkinsonism (P3.049). Neurology. 2018, 90:0. 10.1212\/WNL.90.15_supplement.P3.049","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2017.10.015","article-title":"Resveratrol and pinostilbene confer neuroprotection against aging-related deficits through an ERK1\/2-dependent mechanism","volume":"54","author":"Allen EN","year":"2018","unstructured":"Allen EN, Potdar S, Tapias V, Parmar M, Mizuno CS, Rimando A, Cavanaugh JE. Resveratrol and pinostilbene confer neuroprotection against aging-related deficits through an ERK1\/2-dependent mechanism. J Nutr Biochem. 2018, 54:77-86. 10.1016\/j.jnutbio.2017.10.015","journal-title":"J Nutr Biochem"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-017-2073-z","article-title":"Protective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells","volume":"92","author":"Potdar S","year":"2018","unstructured":"Potdar S, Parmar MS, Ray SD, Cavanaugh JE. Protective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells. Arch Toxicol. 2018, 92:669-77. 10.1007\/s00204-017-2073-z","journal-title":"Arch Toxicol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2013.09.031","article-title":"Role of ERK1, 2, and 5 in dopamine neuron survival during aging","volume":"35","author":"Parmar MS","year":"2014","unstructured":"Parmar MS, Jaumotte JD, Wyrostek SL, Zigmond MJ, Cavanaugh JE. Role of ERK1, 2, and 5 in dopamine neuron survival during aging. Neurobiol Aging. 2014, 35:669-79. 10.1016\/j.neurobiolaging.2013.09.031","journal-title":"Neurobiol Aging"},{"key":"ref8","unstructured":"Understanding Parkinson's. statistics. (2025). Accessed: August 23, 2025: https:\/\/www.parkinson.org\/understanding-parkinsons\/statistics."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07599-1","article-title":"From lab bench to hope: a review of gene therapies in clinical trials for Parkinson's disease and challenges","volume":"45","author":"Grote J","year":"2024","unstructured":"Grote J, Patel N, Bates C, Parmar MS. From lab bench to hope: a review of gene therapies in clinical trials for Parkinson's disease and challenges. Neurol Sci. 2024, 45:4699-710. 10.1007\/s10072-024-07599-1","journal-title":"Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67037","article-title":"Emerging gene therapies for Alzheimer\u2019s and Parkinson\u2019s diseases: an overview of clinical trials and promising candidates","volume":"16","author":"Roberts WS","year":"2024","unstructured":"Roberts WS, Price S, Wu M, Parmar MS. Emerging gene therapies for Alzheimer\u2019s and Parkinson\u2019s diseases: an overview of clinical trials and promising candidates. Cureus. 2024, 16:e67037. 10.7759\/cureus.67037","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.dscb.2024.100163","article-title":"Novel approaches targeting in \u03b1-synuclein for Parkinson\u2019s disease: current progress and future directions for the disease-modifying therapies","volume":"16","author":"Baggett D","year":"2024","unstructured":"Baggett D, Olson A, Parmar MS. Novel approaches targeting in \u03b1-synuclein for Parkinson\u2019s disease: current progress and future directions for the disease-modifying therapies. Brain Disord. 2024, 16:100163. 10.1016\/j.dscb.2024.100163","journal-title":"Brain Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25019","article-title":"The significance of defining preclinical or prodromal Parkinson's disease","volume":"27","author":"Olanow CW","year":"2012","unstructured":"Olanow CW, Obeso JA. The significance of defining preclinical or prodromal Parkinson's disease. Mov Disord. 2012, 27:666-9. 10.1002\/mds.25019","journal-title":"Mov Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020335","article-title":"The challenge of disease-modifying therapies in Parkinson\u2019s disease: role of CSF biomarkers","volume":"10","author":"Paolini Paoletti F","year":"2020","unstructured":"Paolini Paoletti F, Gaetani L, Parnetti L. The challenge of disease-modifying therapies in Parkinson\u2019s disease: role of CSF biomarkers. Biomolecules. 2020, 10:335. 10.3390\/biom10020335","journal-title":"Biomolecules"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.10.002","article-title":"MRI biomarkers of motor and non-motor symptoms in Parkinson's disease","volume":"73","author":"Ryman SG","year":"2020","unstructured":"Ryman SG, Poston KL. MRI biomarkers of motor and non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2020, 73:85-93. 10.1016\/j.parkreldis.2019.10.002","journal-title":"Parkinsonism Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49949-9","article-title":"Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions","volume":"15","author":"Zarkali A","year":"2024","unstructured":"Zarkali A, Thomas GE, Zetterberg H, Weil RS. Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions. Nat Commun. 2024, 15:5661. 10.1038\/s41467-024-49949-9","journal-title":"Nat Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf A","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, et al.. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023, 22:407-17. 10.1016\/s1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","article-title":"Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal","volume":"8","author":"Maroteaux L","year":"1988","unstructured":"Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988, 8:2804-15. 10.1523\/JNEUROSCI.08-08-02804.1988","journal-title":"J Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nature10324","article-title":"\u03b1-synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels T","year":"2011","unstructured":"Bartels T, Choi JG, Selkoe DJ. \u03b1-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011, 477:107-10. 10.1038\/nature10324","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.11.6469","article-title":"\u03b1-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies","volume":"95","author":"Spillantini MG","year":"1998","unstructured":"Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. \u03b1-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998, 95:6469-73. 10.1073\/pnas.95.11.6469","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos MH","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, et al.. Mutation in the \u03b1-synuclein gene identified in families with Parkinson's disease. Science. 1997, 276:2045-7. 10.1126\/science.276.5321.2045","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-024-05190-y","article-title":"Advancing Parkinson's diagnosis: seed amplification assay for \u03b1-synuclein detection in minimally invasive samples","volume":"480","author":"Carrazana E","year":"2025","unstructured":"Carrazana E, Montalb\u00e1n-Guti\u00e9rrez L, Chana-Cuevas P, Salvadores N. Advancing Parkinson's diagnosis: seed amplification assay for \u03b1-synuclein detection in minimally invasive samples. Mol Cell Biochem. 2025, 480:3297-314. 10.1007\/s11010-024-05190-y","journal-title":"Mol Cell Biochem"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010389","article-title":"The \u03b1-synuclein seeding amplification assay for Parkinson\u2019s disease","volume":"26","author":"Yi LX","year":"2025","unstructured":"Yi LX, Tan EK, Zhou ZD. The \u03b1-synuclein seeding amplification assay for Parkinson\u2019s disease. Int J Mol Sci. 2025, 26:389. 10.3390\/ijms26010389","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29766","article-title":"Detecting misfolded \u03b1-synuclein in blood years before the diagnosis of Parkinson\u2019s disease","volume":"39","author":"Kluge A","year":"2024","unstructured":"Kluge A, Schaeffer E, Bunk J, et al.. Detecting misfolded \u03b1-synuclein in blood years before the diagnosis of Parkinson\u2019s disease. Mov Disord. 2024, 39:1289-99. 10.1002\/mds.29766","journal-title":"Mov Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14569","article-title":"Antibody-based methods for the measurement of \u03b1-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study","volume":"149","author":"Mollenhauer B","year":"2019","unstructured":"Mollenhauer B, Bowman FD, Drake D, et al.. Antibody-based methods for the measurement of \u03b1-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. J Neurochem. 2019, 149:126-38. 10.1111\/jnc.14569","journal-title":"J Neurochem"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson's disease: a systematic review and meta-analysis","volume":"32","author":"Eusebi P","year":"2017","unstructured":"Eusebi P, Giannandrea D, Biscetti L, et al.. Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2017, 32:1389-400. 10.1002\/mds.27110","journal-title":"Mov Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease","volume":"6","author":"Hansson O","year":"2014","unstructured":"Hansson O, Hall S, Ohrfelt A, et al.. Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther. 2014, 6:25. 10.1186\/alzrt255","journal-title":"Alzheimers Res Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.08.024","article-title":"Decreased \u03b1-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease","volume":"349","author":"Tokuda T","year":"2006","unstructured":"Tokuda T, Salem SA, Allsop D, et al.. Decreased \u03b1-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun. 2006, 349:162-6. 10.1016\/j.bbrc.2006.08.024","journal-title":"Biochem Biophys Res Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease","volume":"133","author":"Hong Z","year":"2010","unstructured":"Hong Z, Shi M, Chung KA, et al.. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010, 133:713-26. 10.1093\/brain\/awq008","journal-title":"Brain"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal \u03b1-synuclein is likely CNS-derived and increased in Parkinson's disease","volume":"128","author":"Shi M","year":"2014","unstructured":"Shi M, Liu C, Cook TJ, et al.. Plasma exosomal \u03b1-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol. 2014, 128:639-50. 10.1007\/s00401-014-1314-y","journal-title":"Acta Neuropathol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052285","article-title":"\u03b1-synuclein and anti-\u03b1-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls","volume":"7","author":"Smith LM","year":"2012","unstructured":"Smith LM, Schiess MC, Coffey MP, Klaver AC, Loeffler DA. \u03b1-synuclein and anti-\u03b1-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS One. 2012, 7:e52285. 10.1371\/journal.pone.0052285","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22928","article-title":"Plasma \u03b1-synuclein in patients with Parkinson's disease with and without treatment","volume":"25","author":"Duran R","year":"2010","unstructured":"Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F. Plasma \u03b1-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord. 2010, 25:489-93. 10.1002\/mds.22928","journal-title":"Mov Disord"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"40","author":"Bougea A","year":"2019","unstructured":"Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Vekrelis K, Kapaki E. Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis. Neurol Sci. 2019, 40:929-38. 10.1007\/s10072-019-03738-1","journal-title":"Neurol Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.4398","article-title":"Neuronally derived extracellular vesicle \u03b1-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease","volume":"81","author":"Yan S","year":"2024","unstructured":"Yan S, Jiang C, Janzen A, et al.. Neuronally derived extracellular vesicle \u03b1-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease. JAMA Neurol. 2024, 81:59-68. 10.1001\/jamaneurol.2023.4398","journal-title":"JAMA Neurol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi A","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, et al.. Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med. 2023, 29:1448-55. 10.1038\/s41591-023-02358-9","journal-title":"Nat Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4243","article-title":"When do \u03b1-synucleinopathies start? An epidemiological timeline: a review","volume":"75","author":"Savica R","year":"2018","unstructured":"Savica R, Boeve BF, Mielke MM. When do \u03b1-synucleinopathies start? An epidemiological timeline: a review. JAMA Neurol. 2018, 75:503-9. 10.1001\/jamaneurol.2017.4243","journal-title":"JAMA Neurol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-019-0155-y","article-title":"Erythrocytic \u03b1-synuclein as a potential biomarker for Parkinson\u2019s disease","volume":"8","author":"Tian C","year":"2019","unstructured":"Tian C, Liu G, Gao L, et al.. Erythrocytic \u03b1-synuclein as a potential biomarker for Parkinson\u2019s disease. Transl Neurodegener. 2019, 8:15. 10.1186\/s40035-019-0155-y","journal-title":"Transl Neurodegener"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03031-1","article-title":"Fluorescence-tagged salivary small extracellular vesicles as a nanotool in early diagnosis of Parkinson's disease","volume":"21","author":"Rastogi S","year":"2023","unstructured":"Rastogi S, Rani K, Rai S, et al.. Fluorescence-tagged salivary small extracellular vesicles as a nanotool in early diagnosis of Parkinson's disease. BMC Med. 2023, 21:335. 10.1186\/s12916-023-03031-1","journal-title":"BMC Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01873-1","article-title":"A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson's disease","volume":"12","author":"Wang Z","year":"2024","unstructured":"Wang Z, Gilliland T, Kim HJ, et al.. A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson's disease. Acta Neuropathol Commun. 2024, 12:167. 10.1186\/s40478-024-01873-1","journal-title":"Acta Neuropathol Commun"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107088","article-title":"Combining salivary \u03b1-synuclein seeding activity and miRNA-29a to distinguish Parkinson's disease and multiple system atrophy","volume":"127","author":"Luan M","year":"2024","unstructured":"Luan M, Wei L, Sun Y, et al.. Combining salivary \u03b1-synuclein seeding activity and miRNA-29a to distinguish Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord. 2024, 127:107088. 10.1016\/j.parkreldis.2024.107088","journal-title":"Parkinsonism Relat Disord"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2022MD8044","article-title":"Investigation of nerve fibers in the skin by biopsy: technical aspects, indications, and contribution to diagnosis of small-fiber neuropathy","volume":"20","author":"Raicher I","year":"2022","unstructured":"Raicher I, Ravagnani LH, Correa SG, Dobo C, Mangueira CL, Macarenco RS. Investigation of nerve fibers in the skin by biopsy: technical aspects, indications, and contribution to diagnosis of small-fiber neuropathy. Einstein (Sao Paulo). 2022, 20:eMD8044.","journal-title":"Einstein (Sao Paulo)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000316","article-title":"Skin nerve \u03b1-synuclein deposits: a biomarker for idiopathic Parkinson disease","volume":"82","author":"Donadio V","year":"2014","unstructured":"Donadio V, Incensi A, Leta V, et al.. Skin nerve \u03b1-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology. 2014, 82:1362-9. 10.1212\/WNL.0000000000000316","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0792","article-title":"Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies","volume":"331","author":"Gibbons CH","year":"2024","unstructured":"Gibbons CH, Levine T, Adler C, et al.. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA. 2024, 331:1298-306. 10.1001\/jama.2024.0792","journal-title":"JAMA"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","volume":"78","author":"Wang Z","year":"2020","unstructured":"Wang Z, Becker K, Donadio V, et al.. Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol. 2020, 78:1-11. 10.1001\/jamaneurol.2020.3311","journal-title":"JAMA Neurol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-023-01419-4","article-title":"Retinal changes in Parkinson\u2019s disease: a non-invasive biomarker for early diagnosis","volume":"43","author":"Subramaniam MD","year":"2023","unstructured":"Subramaniam MD, Aishwarya Janaki P, Abishek Kumar B, Gopalarethinam J, Nair AP, Mahalaxmi I, Vellingiri B. Retinal changes in Parkinson\u2019s disease: a non-invasive biomarker for early diagnosis. Cell Mol Neurobiol. 2023, 43:3983-96. 10.1007\/s10571-023-01419-4","journal-title":"Cell Mol Neurobiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.227","article-title":"The retina as a window to the brain-from eye research to CNS disorders","volume":"9","author":"London A","year":"2013","unstructured":"London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013, 9:44-53. 10.1038\/nrneurol.2012.227","journal-title":"Nat Rev Neurol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00348-y","article-title":"Starburst amacrine cells, involved in visual motion perception, loose their synaptic input from dopaminergic amacrine cells and degenerate in Parkinson's disease patients","volume":"12","author":"S\u00e1nchez-S\u00e1ez X","year":"2023","unstructured":"S\u00e1nchez-S\u00e1ez X, Ortu\u00f1o-Lizar\u00e1n I, S\u00e1nchez-Castillo C, Lax P, Cuenca N. Starburst amacrine cells, involved in visual motion perception, loose their synaptic input from dopaminergic amacrine cells and degenerate in Parkinson's disease patients. Transl Neurodegener. 2023, 12:17. 10.1186\/s40035-023-00348-y","journal-title":"Transl Neurodegener"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27392","article-title":"Phosphorylated \u03b1-synuclein in the retina is a biomarker of Parkinson's disease pathology severity","volume":"33","author":"Ortu\u00f1o-Lizar\u00e1n I","year":"2018","unstructured":"Ortu\u00f1o-Lizar\u00e1n I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N. Phosphorylated \u03b1-synuclein in the retina is a biomarker of Parkinson's disease pathology severity. Mov Disord. 2018, 33:1315-24. 10.1002\/mds.27392","journal-title":"Mov Disord"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00570-5","article-title":"\u03b1-synuclein pathology in post-mortem retina and optic nerve is specific for \u03b1-synucleinopathies","volume":"9","author":"Hart de Ruyter FJ","year":"2023","unstructured":"Hart de Ruyter FJ, Morrema TH, den Haan J, et al.. \u03b1-synuclein pathology in post-mortem retina and optic nerve is specific for \u03b1-synucleinopathies. NPJ Parkinsons Dis. 2023, 9:124. 10.1038\/s41531-023-00570-5","journal-title":"NPJ Parkinsons Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106872","article-title":"Early detection of Parkinson's disease: retinal functional impairments as potential biomarkers","volume":"208","author":"Soto Linan V","year":"2025","unstructured":"Soto Linan V, Rioux V, Peralta M 3rd, Dupr\u00e9 N, H\u00e9bert M, L\u00e9vesque M. Early detection of Parkinson's disease: retinal functional impairments as potential biomarkers. Neurobiol Dis. 2025, 208:106872. 10.1016\/j.nbd.2025.106872","journal-title":"Neurobiol Dis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.004","article-title":"The in situ structure of Parkinson\u2019s disease-linked LRRK2","volume":"182","author":"Watanabe R","year":"2020","unstructured":"Watanabe R, Buschauer R, B\u00f6hning J, et al.. The in situ structure of Parkinson\u2019s disease-linked LRRK2. Cell. 2020, 182:1508-18.e16. 10.1016\/j.cell.2020.08.004","journal-title":"Cell"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00660-20","article-title":"The cell biology of LRRK2 in Parkinson\u2019s disease","volume":"41","author":"Usmani A","year":"2021","unstructured":"Usmani A, Shavarebi F, Hiniker A. The cell biology of LRRK2 in Parkinson\u2019s disease. Mol Cell Biol. 2021, 41:0. 10.1128\/MCB.00660-20","journal-title":"Mol Cell Biol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson's disease","volume":"10","author":"Di Maio R","year":"2018","unstructured":"Di Maio R, Hoffman EK, Rocha EM, et al.. LRRK2 activation in idiopathic Parkinson's disease. Sci Transl Med. 2018, 10:eaar5429. 10.1126\/scitranslmed.aar5429","journal-title":"Sci Transl Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study","volume":"7","author":"Healy DG","year":"2008","unstructured":"Healy DG, Falchi M, O'Sullivan SS, et al.. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-90. 10.1016\/S1474-4422(08)70117-0","journal-title":"Lancet Neurol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00526","article-title":"Quantitative measurements of LRRK2 in human cerebrospinal fluid demonstrates increased levels in G2019S patients","volume":"14","author":"Mabrouk OS","year":"2020","unstructured":"Mabrouk OS, Chen S, Edwards AL, Yang M, Hirst WD, Graham DL. Quantitative measurements of LRRK2 in human cerebrospinal fluid demonstrates increased levels in G2019S patients. Front Neurosci. 2020, 14:526. 10.3389\/fnins.2020.00526","journal-title":"Front Neurosci"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.892899","article-title":"WHOPPA enables parallel assessment of leucine-rich repeat kinase 2 and glucocerebrosidase enzymatic activity in Parkinson\u2019s disease monocytes","volume":"16","author":"Wallings RL","year":"2022","unstructured":"Wallings RL, Hughes LP, Staley HA, et al.. WHOPPA enables parallel assessment of leucine-rich repeat kinase 2 and glucocerebrosidase enzymatic activity in Parkinson\u2019s disease monocytes. Front Cell Neurosci. 2022, 16:892899. 10.3389\/fncel.2022.892899","journal-title":"Front Cell Neurosci"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00336-5","article-title":"Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts","volume":"8","author":"Petropoulou-Vathi L","year":"2022","unstructured":"Petropoulou-Vathi L, Simitsi A, Valkimadi PE, et al.. Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts. NPJ Parkinsons Dis. 2022, 8:73. 10.1038\/s41531-022-00336-5","journal-title":"NPJ Parkinsons Dis"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29043","article-title":"Elevated urinary Rab10 phosphorylation in idiopathic Parkinson disease","volume":"37","author":"Wang S","year":"2022","unstructured":"Wang S, Unnithan S, Bryant N, et al.. Elevated urinary Rab10 phosphorylation in idiopathic Parkinson disease. Mov Disord. 2022, 37:1454-64. 10.1002\/mds.29043","journal-title":"Mov Disord"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30319-9","article-title":"Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study","volume":"19","author":"Simuni T","year":"2020","unstructured":"Simuni T, Uribe L, Cho HR, et al.. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol. 2020, 19:71-80. 10.1016\/S1474-4422(19)30319-9","journal-title":"Lancet Neurol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00624-8","article-title":"A potential patient stratification biomarker for Parkinson\u00b4s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells","volume":"10","author":"Naaldijk Y","year":"2024","unstructured":"Naaldijk Y, Fern\u00e1ndez B, Fasiczka R, et al.. A potential patient stratification biomarker for Parkinson\u00b4s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells. NPJ Parkinsons Dis. 2024, 10:12. 10.1038\/s41531-023-00624-8","journal-title":"NPJ Parkinsons Dis"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28890","article-title":"Mild chronic colitis triggers parkinsonism in LRRK2 mutant mice through activating TNF-\u03b1 pathway","volume":"37","author":"Lin CH","year":"2022","unstructured":"Lin CH, Lin HY, Ho EP, et al.. Mild chronic colitis triggers parkinsonism in LRRK2 mutant mice through activating TNF-\u03b1 pathway. Mov Disord. 2022, 37:745-57. 10.1002\/mds.28890","journal-title":"Mov Disord"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.06.017","article-title":"Parkinson's Progression Markers Initiative brain autopsy program","volume":"101","author":"Bukhari SA","year":"2022","unstructured":"Bukhari SA, Nudelman KN, Rumbaugh M, et al.. Parkinson's Progression Markers Initiative brain autopsy program. Parkinsonism Relat Disord. 2022, 101:62-5. 10.1016\/j.parkreldis.2022.06.017","journal-title":"Parkinsonism Relat Disord"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich A","year":"2004","unstructured":"Zimprich A, Biskup S, Leitner P, et al.. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004, 44:601-7. 10.1016\/j.neuron.2004.11.005","journal-title":"Neuron"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20731","article-title":"LRRK2 and Lewy body disease","volume":"59","author":"Ross OA","year":"2006","unstructured":"Ross OA, Toft M, Whittle AJ, et al.. LRRK2 and Lewy body disease. Ann Neurol. 2006, 59:388-93. 10.1002\/ana.20731","journal-title":"Ann Neurol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/bies.200900163","article-title":"Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, \u03b1-synuclein, and tau","volume":"32","author":"Taymans JM","year":"2010","unstructured":"Taymans JM, Cookson MR. Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, \u03b1-synuclein, and tau. Bioessays. 2010, 32:227-35. 10.1002\/bies.200900163","journal-title":"Bioessays"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-019-09798-4","article-title":"Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease","volume":"51","author":"Dolgacheva LP","year":"2019","unstructured":"Dolgacheva LP, Berezhnov AV, Fedotova EI, Zinchenko VP, Abramov AY. Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease. J Bioenerg Biomembr. 2019, 51:175-88. 10.1007\/s10863-019-09798-4","journal-title":"J Bioenerg Biomembr"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.13-108","article-title":"Oxidized DJ-1 as a possible biomarker of Parkinson's disease","volume":"54","author":"Saito Y","year":"2014","unstructured":"Saito Y. Oxidized DJ-1 as a possible biomarker of Parkinson's disease. J Clin Biochem Nutr. 2014, 54:138-44. 10.3164\/jcbn.13-108","journal-title":"J Clin Biochem Nutr"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9070597","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"9","author":"Chang KH","year":"2020","unstructured":"Chang KH, Chen CM. The role of oxidative stress in Parkinson\u2019s disease. Antioxidants (Basel). 2020, 9:597. 10.3390\/antiox9070597","journal-title":"Antioxidants (Basel)"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1241757","article-title":"Oxidized DJ-1 levels in urine samples as a putative biomarker for Parkinson\u2019s disease","volume":"2018","author":"Jang J","year":"2018","unstructured":"Jang J, Jeong S, Lee SI, Seol W, Seo H, Son I, Ho DH. Oxidized DJ-1 levels in urine samples as a putative biomarker for Parkinson\u2019s disease. Parkinsons Dis. 2018, 2018:1241757. 10.1155\/2018\/1241757","journal-title":"Parkinsons Dis"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/704678","article-title":"Increased DJ-1 in urine exosome of Korean males with Parkinson's disease","volume":"2014","author":"Ho DH","year":"2014","unstructured":"Ho DH, Yi S, Seo H, Son I, Seol W. Increased DJ-1 in urine exosome of Korean males with Parkinson's disease. Biomed Res Int. 2014, 2014:704678. 10.1155\/2014\/704678","journal-title":"Biomed Res Int"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.05.011","article-title":"Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease","volume":"345","author":"Waragai M","year":"2006","unstructured":"Waragai M, Wei J, Fujita M, et al.. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun. 2006, 345:967-72. 10.1016\/j.bbrc.2006.05.011","journal-title":"Biochem Biophys Res Commun"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1038\/srep00954","article-title":"DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease","volume":"2","author":"Lin X","year":"2012","unstructured":"Lin X, Cook TJ, Zabetian CP, et al.. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep. 2012, 2:954. 10.1038\/srep00954","journal-title":"Sci Rep"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2017.12.023","article-title":"Expression of the DJ-1 protein in the serum of Chinese patients with Parkinson's disease","volume":"665","author":"An C","year":"2018","unstructured":"An C, Pu X, Xiao W, Zhang H. Expression of the DJ-1 protein in the serum of Chinese patients with Parkinson's disease. Neurosci Lett. 2018, 665:236-9. 10.1016\/j.neulet.2017.12.023","journal-title":"Neurosci Lett"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2007.11.027","article-title":"Secretion of DJ-1 into the serum of patients with Parkinson's disease","volume":"431","author":"Maita C","year":"2008","unstructured":"Maita C, Tsuji S, Yabe I, et al.. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett. 2008, 431:86-9. 10.1016\/j.neulet.2007.11.027","journal-title":"Neurosci Lett"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00438","article-title":"Increased DJ-1 and \u03b1-synuclein in plasma neural-derived exosomes as potential markers for Parkinson\u2019s disease","volume":"10","author":"Zhao ZH","year":"2018","unstructured":"Zhao ZH, Chen ZT, Zhou RL, Zhang X, Ye QY, Wang YZ. Increased DJ-1 and \u03b1-synuclein in plasma neural-derived exosomes as potential markers for Parkinson\u2019s disease. Front Aging Neurosci. 2018, 10:438. 10.3389\/fnagi.2018.00438","journal-title":"Front Aging Neurosci"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.04.039","article-title":"Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain\/cdk5 pathway proteins","volume":"272","author":"Kanagaraj N","year":"2014","unstructured":"Kanagaraj N, Beiping H, Dheen ST, Tay SS. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain\/cdk5 pathway proteins. Neuroscience. 2014, 272:167-79. 10.1016\/j.neuroscience.2014.04.039","journal-title":"Neuroscience"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1053-4","article-title":"MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson's disease","volume":"15","author":"Yao L","year":"2018","unstructured":"Yao L, Ye Y, Mao H, Lu F, He X, Lu G, Zhang S. MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson's disease. J Neuroinflammation. 2018, 15:13. 10.1186\/s12974-018-1053-4","journal-title":"J Neuroinflammation"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.3224","article-title":"Serum miR-221 serves as a biomarker for Parkinson's disease","volume":"34","author":"Ma W","year":"2016","unstructured":"Ma W, Li Y, Wang C, Xu F, Wang M, Liu Y. Serum miR-221 serves as a biomarker for Parkinson's disease. Cell Biochem Funct. 2016, 34:511-5. 10.1002\/cbf.3224","journal-title":"Cell Biochem Funct"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.11.014","article-title":"Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease","volume":"22","author":"Ding H","year":"2016","unstructured":"Ding H, Huang Z, Chen M, Wang C, Chen X, Chen J, Zhang J. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. Parkinsonism Relat Disord. 2016, 22:68-73. 10.1016\/j.parkreldis.2015.11.014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94734-z","article-title":"Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson's disease","volume":"11","author":"Chen Q","year":"2021","unstructured":"Chen Q, Deng N, Lu K, et al.. Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson's disease. Sci Rep. 2021, 11:15268. 10.1038\/s41598-021-94734-z","journal-title":"Sci Rep"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-016-0253-0","article-title":"MicroRNAs in cerebrospinal fluid as potential biomarkers for Parkinson\u2019s disease and multiple system atrophy","volume":"54","author":"Marques TM","year":"2017","unstructured":"Marques TM, Kuiperij HB, Bruinsma IB, et al.. MicroRNAs in cerebrospinal fluid as potential biomarkers for Parkinson\u2019s disease and multiple system atrophy. Mol Neurobiol. 2017, 54:7736-45. 10.1007\/s12035-016-0253-0","journal-title":"Mol Neurobiol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-230408","article-title":"Using extracellular miRNA signatures to identify patients with LRRK2-related Parkinson\u2019s disease","volume":"14","author":"Braunger LJ","year":"2024","unstructured":"Braunger LJ, Knab F, Gasser T. Using extracellular miRNA signatures to identify patients with LRRK2-related Parkinson\u2019s disease. J Parkinsons Dis. 2024, 14:977-91. 10.3233\/JPD-230408","journal-title":"J Parkinsons Dis"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010404","article-title":"In vivo distribution of \u03b1-synuclein in multiple tissues and biofluids in Parkinson disease","volume":"95","author":"Chahine LM","year":"2020","unstructured":"Chahine LM, Beach TG, Brumm MC, et al.. In vivo distribution of \u03b1-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology. 2020, 95:e1267-84. 10.1212\/WNL.0000000000010404","journal-title":"Neurology"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11101030","article-title":"Polygenic risk scores contribute to personalized medicine of Parkinson\u2019s disease","volume":"11","author":"Dehestani M","year":"2021","unstructured":"Dehestani M, Liu H, Gasser T. Polygenic risk scores contribute to personalized medicine of Parkinson\u2019s disease. J Pers Med. 2021, 11:1030. 10.3390\/jpm11101030","journal-title":"J Pers Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0428","article-title":"Identification of risk loci for Parkinson disease in Asians and comparison of risk between Asians and Europeans: a genome-wide association study","volume":"77","author":"Foo JN","year":"2020","unstructured":"Foo JN, Chew EG, Chung SJ, et al.. Identification of risk loci for Parkinson disease in Asians and comparison of risk between Asians and Europeans: a genome-wide association study. JAMA Neurol. 2020, 77:746-54. 10.1001\/jamaneurol.2020.0428","journal-title":"JAMA Neurol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls MA","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, et al.. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019, 18:1091-102. 10.1016\/s1474-4422(19)30320-5","journal-title":"Lancet Neurol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70011","article-title":"Polygenic risk score combined with transcranial sonography refines Parkinson\u2019s disease risk prediction","volume":"12","author":"Kals M","year":"2025","unstructured":"Kals M, Reigo A, Teder-Laving M, et al.. Polygenic risk score combined with transcranial sonography refines Parkinson\u2019s disease risk prediction. Mov Disord Clin Pract. 2025, 12:928-37. 10.1002\/mdc3.70011","journal-title":"Mov Disord Clin Pract"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X241310722","article-title":"The effect of polygenic risk score on PD risk and phenotype in LRRK2 G2019S and GBA1 carriers","volume":"15","author":"Goldstein O","year":"2025","unstructured":"Goldstein O, Shani S, Gana-Weisz M, et al.. The effect of polygenic risk score on PD risk and phenotype in LRRK2 G2019S and GBA1 carriers. J Parkinsons Dis. 2025, 15:291-9. 10.1177\/1877718X241310722","journal-title":"J Parkinsons Dis"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00178-7","article-title":"Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study","volume":"14","author":"Nalls MA","year":"2015","unstructured":"Nalls MA, McLean CY, Rick J, et al.. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 2015, 14:1002-9. 10.1016\/s1474-4422(15)00178-7","journal-title":"Lancet Neurol"},{"key":"ref89","unstructured":"Retinal biomarkers in Parkinson\u00b4s disease. (2025). Accessed. August 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT06929026?term=NCT06929026&amp;rank=1."},{"key":"ref90","unstructured":"Serum biomarkers in Parkinson\u2019s disease at different stages. (2023). Accessed. August 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05769699."},{"key":"ref91","unstructured":"Towards the validation of a new blood biomarker for the early diagnosis of Parkinson\u2019s disease (BIOPARK). (2024). Accessed. August 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05385315?term=NCT05385315&amp;limit=10&amp;sort=@relevance&amp;rank=1."},{"key":"ref92","unstructured":"Slow wave sleep as a biomarker of rehabilitation-induced cognitive improvement in PD. (2024). Accessed. August 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT04796506?term=NCT04796506&amp;limit=10&amp;sort=@relevance&amp;rank=1."},{"key":"ref93","unstructured":"Quantification of phosphorylated alpha-synuclein in cutaneous biopsies as a prospective biomarker in Parkinson\u2019s disease (Syn-Q). (2025). Accessed. August 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT06621602?term=NCT06621602&amp;limit=10&amp;sort=@relevance&amp;rank=1."},{"key":"ref94","unstructured":"Research on novel biomarkers for early diagnosis of Parkinson\u2019s disease. an observational, multicenter, non-randomized controlled study. (2025). Accessed: August 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT06232772?term=NCT06232772&amp;limit=10&amp;sort=@relevance&amp;rank=1."},{"key":"ref95","unstructured":"Misfolded proteins in the skin of people with Parkinson\u2019s disease and other parkinsonism. (2025). Accessed. August 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT04518059?term=NCT04518059&amp;limit=10&amp;sort=@relevance&amp;rank=1."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/378459-challenges-and-opportunities-of-early-parkinsons-disease-biomarkers--synuclein-leucine-rich-repeat-kinase-2-lrrk2-dj-1-and-micrornas","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:42:32Z","timestamp":1756878152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/378459-challenges-and-opportunities-of-early-parkinsons-disease-biomarkers--synuclein-leucine-rich-repeat-kinase-2-lrrk2-dj-1-and-micrornas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":95,"URL":"https:\/\/doi.org\/10.7759\/cureus.91510","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}